Colombia Opens New Investigation Into Former President Álvaro Uribe Over Paramilitary Allegations 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
DOJ Orders Crackdown on Birth Tourism After Supreme Court Upholds Birthright Citizenship 
California Court Dismisses Trump Administration Lawsuit Against Los Angeles Sanctuary Policy 
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Apple Challenges India Antitrust Probe, Says CCI Copied Rivals’ Claims in App Store Case 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
easyJet Agrees in Principle to £5.23 Billion Castlelake Takeover Offer 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
